@pfeifer1982
Yet another thoroughly comprehensive review, thank you. My only query would be:
Regarding the patent-pending from 2020, surely this would have been provided in the second BLA submission last year, since it appears to meet a reasonable hypothesis of MoA, right? If not, then questions must be asked as to what MSB's management are/were doing.
So if the FDA have already assessed it as a part of the approval process of Ryoncil, then I keep coming back to the key factor for Ryoncil's approval being the FDA's assessment of the adequacy of the P3 trial. Again, what has made them backflip here?
Ann: Investor Presentation, page-545
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $42.45M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.5¢ | 23.0¢ | $7.121K | 30.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40116 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 14000 | 2 |
View Market Depth
| Last trade - 13.10pm 01/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |